Jan Damoiseaux

Dr. Jan Damoiseaux

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
JDJan Damoiseaux
Jan Damoiseaux
LALuis Eduardo Coelho Andrade
Luis Eduardo Coelho Andrade
OCOrlando Gabriel Carballo
Orlando Gabriel Carballo
KCKarsten Conrad
Karsten Conrad
PFPaulo Luiz Carvalho Francescantonio
Paulo Luiz Carvalho Francescantonio
ECEdward K Chan
Edward K Chan
The indirect immunofluorescence assay (IIFA) on HEp-2 cells is widely used for detection of antinuclear antibodies (ANA). The dichotomous outcome, negative or positive, is integrated in diagnostic and classification criteria for several systemic autoimmune diseases. However, the HEp-2 IIFA test has much more to offer: besides the titre or fluorescence intensity, it also provides fluorescence pattern(s). The latter include the nucleus and the cytoplasm of interphase cells as well as patterns associated with mitotic cells. The International Consensus on ANA Patterns (ICAP) initiative has previously reached consensus on the nomenclature and definitions of HEp-2 IIFA patterns. In the current paper, the ICAP consensus is presented on the clinical relevance of the 29 distinct HEp-2 IIFA patterns. This clinical relevance is primarily defined within the context of the suspected disease and includes recommendations for follow-up testing. The discussion includes how this information may benefit the clinicians in daily practice and how the knowledge can be used to further improve diagnostic and classification criteria.

1 September 2020 in Clinical Immunology
Verified
Journal Article
Open access
JDJan Damoiseaux
Jan Damoiseaux
The interleukin (IL)-2 - IL-2 receptor (IL-2R) pathway is important in immunity, but is also involved in maintenance of self-tolerance. This paradox is further complicated by shedding of the IL-2Rα chain, revealing soluble (s)IL-2R. Binding of IL-2 to sIL-2R may either reduce or enhance responses depending on the target cell being involved in immunity or self-tolerance. Since sIL-2R levels are increasingly measured in clinical practice, it is detrimental for clinical interpretation to understand the possible functional impact of IL-2R shedding. In this review the role of the IL-2 - IL-2R pathway is explored and the conflicting results on the function of sIL-2R are summarized. Finally, the added value of measuring sIL-2R in different types of diseases is being elaborated upon in terms of diagnosis, follow-up, and prognosis. Adequate interpretation of results is hampered by the apparent gap in our knowledge about the functional role of sIL-2R in immunity and tolerance.

1 March 2019 in Autoimmunity Reviews
Verified
Journal Article
Open access
JDJan Damoiseaux
Jan Damoiseaux
JVJean-Baptiste Vulsteke
Jean-Baptiste Vulsteke
CTChih-Wei Tseng
Chih-Wei Tseng
APAnouk C.M. Platteel
Anouk C.M. Platteel
YPYves Piette
Yves Piette
XBXavier Bossuyt
Xavier Bossuyt
Idiopathic inflammatory myopathies (IIM) are a group of diseases characterized by immune-mediated muscular lesions that may be associated with extra-muscular manifestations involving skin, lungs, heart or joints. Four main groups of IIM can be distinguished: dermatomyositis (DM), overlap myositis including mainly anti-synthetase syndrome (ASS), immune mediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM). Myositis-specific autoantibodies (MSA) are increasingly recognized as valuable tools for diagnosis, classification and prognosis of IIM. For example, ASS is associated with anti-aminoacyl tRNA synthetase antibodies (anti-Jo-1, PL-7, PL-12, …), IMNM with anti-SRP and anti-HMGCR; IBM with anti-cytosolic 5'nucleotidase 1A (cN1A), and DM with anti-Mi-2, anti-MDA-5, anti-TIF-1γ, anti-NXP-2 and anti-SAE. Moreover, anti-MDA-5 is associated with amyopathic myositis and interstitial lung disease and anti-TIF-1γ and anti-NXP-2 with juvenile DM as well as malignancy in patients >40 years. Most MSA have initially been discovered by immunoprecipitation. In routine laboratories, however, MSA are screened for by indirect immunofluorescence and identified by (automated) monospecific immunoassays or by multispecific immunoassays (mainly line/dot immunoassays). Validation of these (multispecific) assays is a challenge as the antibodies are rare and the assays diverse. In this review, we give an overview of the (clinical) performance characteristics of monospecific assays as well as of multispecific assays for detection of MSA. Although most assays are clinically useful, there are differences between techniques and between manufacturers. We discuss that efforts are needed to harmonize and standardize detection of MSA.

30 January 2016 in Autoimmunity Highlights
Verified
Journal Article
Open access
PDF file
JDJan Damoiseaux
Jan Damoiseaux
CMCarlos A. von Mühlen
Carlos A. von Mühlen
ITIgnacio Garcia-De La Torre
Ignacio Garcia-De La Torre
OCOrlando Gabriel Carballo
Orlando Gabriel Carballo
WCWilson de Melo Cruvinel
Wilson de Melo Cruvinel
KCKarsten Conrad
Karsten Conrad
The International Consensus on ANA Patterns (ICAP) was initiated as a workshop aiming to thoroughly discuss and achieve consensus regarding the morphological patterns observed in the indirect immunofluorescence assay on HEp-2 cells. One of the topics discussed at the second ICAP workshop, and addressed in this paper, was the harmonization of reporting ANA test results. This discussion centered on the issue if cytoplasmic and mitotic patterns should be reported as positive or negative. This report outlines the issues that impact on two major different reporting methods. Although it was appreciated by all participants that cytoplasmic and mitotic patterns are clinically relevant, implications for existing diagnostic/classification criteria for ANA-associated diseases in particular hampered a final consensus on this topic. Evidently, a more concerted action of all relevant stakeholders is required. Future ICAP workshops may help to facilitate this action.

3 November 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
MBMatthias H. Busch
Matthias H. Busch
STSjoerd A.M.E.G. Timmermans
Sjoerd A.M.E.G. Timmermans
MNMagdolna Nagy
Magdolna Nagy
MVMayken Visser
Mayken Visser
JHJoram Huckriede
Joram Huckriede
PPPieter van Paassen
Pieter van Paassen

1 January 2010 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
BWBenjamin Wilde
Benjamin Wilde
MTMarielle Thewissen
Marielle Thewissen
JDJan Damoiseaux
Jan Damoiseaux
PPPieter van Paassen
Pieter van Paassen
OWOliver Witzke
Oliver Witzke
JTJan Willem Cohen Tervaert
Jan Willem Cohen Tervaert
Anti-neutrophil cytoplasmic antibody (ANCA) - associated vasculitis (AAV) is a life-threatening autoimmune disease characterized by an antibody-mediated glomerulonephritis and necrotizing vasculitis. Apart from antibodies, T cells are also involved in disease pathogenesis. This review stresses the hallmarks of T cell-mediated pathology in AAV and highlights the characteristics of lesional and circulating T cells in the immune response in AAV. Circulating effector T-cell populations are expanded and are in a persistent state of activation. Circulating regulatory T-cell subsets are less well characterized but seem to be impaired in function. Lesional effector T cells are present in granulomas, vasculitic lesions, and nephritis. Lesional T cells usually show pro-inflammatory properties and promote granuloma formation. Apart from T cells, dendritic cells are abundantly present at the sites of inflammation and locally orchestrate the immune response. Targeting the above-mentioned T cell-mediated disease mechanisms will potentially provide powerful therapeutic tools for AAV.